Cytori Therapeutics Sees Volume Surge Late In Day
by Hisham S. Ayoub, DMD
BioHealth Investor
Shares of Cytori Therapeutics (CYTX) saw a large spike in volume late in the day on Tuesday with a corresponding jump in price. There were no news or significant events that could be detected.
Cytori develops the Celution System for harvesting regenerative stem cells from fat tissue. The company has also developed a method for utilizing these cells in reconstructive surgery.
Cytori recently divested its Marcopore Biosurgery unit, and is now fully focused on the Celution System for use in breast reconstruction following partial mastectomies,
and for growing new heart tissue in cardiac ischemic patients. It expects to have European approval for its first product in 3 years, and U.S. approval in 5 years.
Insiders, including CEO Mark Calhoun and CFO Mark Saad, bought plenty of shares from August to December of 2006.
Shares of Cytori opened on Tuesday at $5.75, jumped to $6.29 at the peak of the late-day volume surge, before ending the day at $5.93.
The next few days might prove rather interesting for Cytori shareholders.
RELATED READING:
- There He Goes Again - The Stem Cell Dogma
- FDA Green Lights Harvest’s Stem Cell Trial
- US Stem Cell Policy: ceding the competitive edge
BioHealth Investor.com
_____________________
BioHealth Investor
Shares of Cytori Therapeutics (CYTX) saw a large spike in volume late in the day on Tuesday with a corresponding jump in price. There were no news or significant events that could be detected.Cytori develops the Celution System for harvesting regenerative stem cells from fat tissue. The company has also developed a method for utilizing these cells in reconstructive surgery.
Cytori recently divested its Marcopore Biosurgery unit, and is now fully focused on the Celution System for use in breast reconstruction following partial mastectomies,
and for growing new heart tissue in cardiac ischemic patients. It expects to have European approval for its first product in 3 years, and U.S. approval in 5 years.Insiders, including CEO Mark Calhoun and CFO Mark Saad, bought plenty of shares from August to December of 2006.
Shares of Cytori opened on Tuesday at $5.75, jumped to $6.29 at the peak of the late-day volume surge, before ending the day at $5.93.
The next few days might prove rather interesting for Cytori shareholders.
RELATED READING:
- There He Goes Again - The Stem Cell Dogma
- FDA Green Lights Harvest’s Stem Cell Trial
- US Stem Cell Policy: ceding the competitive edge
BioHealth Investor.com
_____________________
posted by Nico at
7:11 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home